Medication info
Empagliflozin 10 mg Tablet (Empagliflozin)

Empagliflozin 10 mg Tablet (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pale yellow, round film-coated tablet
Packaging
PTP - 30 tablets/PTP [10 tablets/PTP x 3], PTP - 10 tablets/PTP [10 tablets/PTP x 1]
Approval status
Active

MFDS item code 202105449 · Approved 2021.07.19 · Insurance code 642507860

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is an adjunct to diet and exercise used to improve blood sugar control in adults with type 2 diabetes. It can be used as monotherapy or in combination with other medications. Patients with type 2 diabetes who do not have adequate blood sugar control and have cardiovascular disease should refer to the medical professional for specific precautions. This medication helps effectively control blood sugar levels in patients with type 2 diabetes, improving overall health management.

How to take

Adult dose

The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Precautions

This medication should not be administered to certain patients. First, it should not be used by individuals who are allergic to the active substance or other ingredients in this medication. Moreover, this medication should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, specifically with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m2 or end-stage renal disease, or those undergoing dialysis, are also not suitable candidates for this medication. This medication contains lactose, so it should not be taken by patients with lactose intolerance or galactose metabolism disorders. Caution is required when using this medication in patients with mild renal impairment. In particular, it is not recommended to initiate treatment in patients with an eGFR of less than 60 mL/min/1.73m2, and kidney function should be regularly monitored during treatment. If kidney function deteriorates further and falls below an eGFR of 45 mL/min/1.73m2, this medication should be discontinued. The effectiveness of this medication is not expected in patients with end-stage renal disease or those undergoing dialysis. In patients with heart failure, especially those with severe heart failure, data on the safety and efficacy of this medication is limited, and caution is advised. There may be an increased risk of hypoglycemia when this medication is used in conjunction with insulin or sulfonylureas, so dosage adjustments of those medications may be necessary. Various adverse reactions may occur when taking this medication. The most common side effect is hypoglycemia, especially when used alongside insulin or sulfonylureas, which increases the hypoglycemia risk. Genital infections such as vulvovaginitis, balanitis, and other genital infections may also occur. Increased urination frequency, urinary tract infections, and reduced fluid volume (dehydration, hypotension, etc.) have also been reported. Severe metabolic abnormalities such as ketoacidosis may occur in relation to this medication, and ketoacidosis can manifest even when blood sugar levels are not markedly elevated, so caution is necessary. If symptoms of ketoacidosis are suspected, consult a doctor immediately and discontinue treatment. In elderly patients, especially those over 75 years of age, the risk of fluid volume loss is higher, so it is essential to closely monitor fluid status and blood pressure when this medication is administered. This medication can affect kidney function, so regular kidney function assessments should be performed before and during treatment. There may be an increased risk of genital fungal infections while taking this medication, so treatment should be initiated promptly if symptoms arise. Caution is required when driving or operating machinery due to the risk of hypoglycemia, especially when used in conjunction with insulin or sulfonylureas. The use of this medication is not recommended during pregnancy, and it should be discontinued if pregnancy is confirmed. In the case of breastfeeding, it is advisable to stop breastfeeding, as this medication may be secreted in breast milk. The safety and efficacy of this medication have not been established in children under 18 years of age, and usage in this population is not recommended. No specific toxic symptoms have been reported in cases of overdose; however, appropriate treatment should be given based on clinical conditions in case of overdose. Finally, this medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • Hypoglycemia
  • ketoacidosis
  • vulvovaginitis
  • balanitis
  • other genital infections
  • increased urination
  • urinary difficulty
  • interstitial nephritis
  • itching
  • rash
Show 12 more
  • urticaria
  • angioedema
  • decreased fluid volume
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urinary tract infection
  • urosepsis
  • pyelonephritis
  • perineal necrosis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly closed container. Additionally, it is important to keep the medication at room temperature, between 1 to 30 degrees Celsius, to maintain its effectiveness.

Appearance and packaging

Appearance

Pale yellow, round film-coated tablet

Package unit

PTP - 30 tablets/PTP [10 tablets/PTP x 3], PTP - 10 tablets/PTP [10 tablets/PTP x 1]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.